{'52WeekChange': 0.11928928,
 'SandP52WeekChange': 0.0644362,
 'address1': '5 Nahum Heftsadie Street',
 'address2': 'Givaat Shaul',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.45,
 'askSize': 800,
 'averageDailyVolume10Day': 227175,
 'averageVolume': 400909,
 'averageVolume10days': 227175,
 'beta': None,
 'beta3Year': None,
 'bid': 4.37,
 'bidSize': 2900,
 'bookValue': 0.75,
 'category': None,
 'circulatingSupply': None,
 'city': 'Jerusalem',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.65,
 'dayLow': 4.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.312,
 'enterpriseToRevenue': None,
 'enterpriseValue': 114764928,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.6165714,
 'fiftyTwoWeekHigh': 7.7,
 'fiftyTwoWeekLow': 2.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20984209,
 'forwardEps': -1.13,
 'forwardPE': -3.9026546,
 'fromCurrency': None,
 'fullTimeEmployees': 79,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.52459,
 'heldPercentInstitutions': 0.33249,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/gamida-cell.com',
 'longBusinessSummary': 'Gamida Cell Ltd., a clinical stage biopharmaceutical '
                        'company, focuses on developing cell therapies to cure '
                        'cancer, and rare and serious hematologic diseases. '
                        "The company's lead product candidate is NiCord, a "
                        'nicotinamide (NAM)-expanded cord blood cell therapy '
                        'that is in Phase III studies in patients with '
                        'high-risk hematologic malignancies, as well as in '
                        'Phase I/II studies in patients with severe aplastic '
                        'anemia. It is also developing NAM-NK, an innate '
                        'immunotherapy, which is in Phase I studies for the '
                        'treatment of relapsed or refractory non-Hodgkin '
                        'lymphoma and multiple myeloma. The company was '
                        'founded in 1998 and is headquartered in Jerusalem, '
                        'Israel.',
 'longName': 'Gamida Cell Ltd.',
 'market': 'us_market',
 'marketCap': 217517952,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_556352',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -29446000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.65,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 2 659 5666',
 'previousClose': 4.59,
 'priceHint': 4,
 'priceToBook': 5.8799996,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.65,
 'regularMarketDayLow': 4.36,
 'regularMarketOpen': 4.65,
 'regularMarketPreviousClose': 4.59,
 'regularMarketPrice': 4.65,
 'regularMarketVolume': 247152,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 49323800,
 'sharesPercentSharesOut': 0.0004,
 'sharesShort': 17988,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 41893,
 'shortName': 'Gamida Cell Ltd.',
 'shortPercentOfFloat': 0.0005,
 'shortRatio': 0.07,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'GMDA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.429,
 'twoHundredDayAverage': 4.4184175,
 'volume': 247152,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.gamida-cell.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '91340'}